Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. (25th May 2020)

• Record Type: Journal Article
• Authors: Genovese, Mark C; Mysler, Eduardo; Tomita, Tetsuya; Papp, Kim A; Salvarani, Carlo; Schwartzman, Sergio; Gallo, Gaia; Patel, Himanshu; Lisse, Jeffrey R; Kronbergs, Andris; Leage, Soyi Liu; Adams, David H; Xu, Wen; Marzo-Ortega, Helena; Lebwohl, Mark G
• Is Part Of: Rheumatology. Volume 59:Number 12(2020)
• Page Start: 3834
• Page End: 3844
• Publication Date: 2020-05-25
• Subjects: ixekizumab -- IL-17 -- safety -- psoriasis -- psoriatic arthritis -- axial spondyloarthritis; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keaa189
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objectives: The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA. Methods: Integrated safety data from 21 clinical trials are presented by indication in patients who received at least one dose of ixekizumab. Adverse events (AEs) and treatment-emergent adverse events (TEAEs) adjusted incidence rates (IRs) per 100 patient-years (PY) up to 5 years' exposure are reported. Results: A total of 8228 patients with an ixekizumab exposure of 20 895.9 PY were included in this analysis. The most common TEAEs were nasopharyngitis, upper respiratory tract infection and injection-site reactions. Across populations, IRs were low for AEs leading to discontinuation (IRs ≤5.1 per 100 PY), serious AEs (IRs ≤6.0 per 100 PY) and death (IRs ≤0.3 per 100 PY). The most reported TEAEs of special interest were infections (IRs ≤35.8 per 100 PY). Patients rarely reported malignancies (IR ≤0.8), IBD including ulcerative colitis and Crohn's disease (IR ≤0.8) and major adverse cardiovascular events (IR ≤0.5). TEAEs were most commonly reported the first 2 years of exposure with ixekizumab and IR decreased over the years (infections, injection-site reactions and depression) or remained constant over the entire treatment period (serious infections, major adverse cardiovascular events, malignancies and IBD). Conclusion: This long-term analysis on the safety of ixekizumab was consistent with previously published reports and did not show any new safety signals. The safety profile and tolerability reported in this integrated analysis remained consistent with the known safety profile for ixekizumab.